SEATTLE, WA--(Marketwired - Mar 24, 2015) - Atossa Genetics Inc. (NASDAQ: ATOS), announced today that it has launched the FullCYTE Breast Aspirator in the United States.

Dr. Steven Quay, Chairman, CEO & President of Atossa Genetics, commented, "Launching and commercializing the FullCYTE device in the U.S. is one of our key objectives for 2015 and we are pleased to announce that we have taken significant steps forward in achieving this goal. Our contract manufacturer has produced an initial inventory of FullCYTE Breast Aspirators. Two leading healthcare providers have placed orders which are now being processed by our national distributors." 

Dr. Quay continued: "Atossa is focused on four key objectives in 2015 for the benefit of all of our stakeholders, especially women with serious breast disease:

  • Launching and commercializing the FullCYTE Breast Aspirator in the U.S. market;

  • Launching and commercializing the CE-marked ForeCYTE Breast Aspirator in the EU, and other non-U.S. markets

  • Achieving top-line combined gross revenue of $8.0 million from medical device sales and laboratory services, including our pharmacogenomics test offering, and;

  • Initiating pharmaceutical clinical trials in women for the treatment of serious breast diseases via local delivery of pharmaceuticals, potentially reducing systemic adverse events.

We recently launched our ForeCYTE Breast Aspirator in the EU and now launching the FullCYTE Breast Aspirator in the U.S. significantly advances our key objectives. We look forward to announcing additional progress on each of these important objectives over the coming months."

About Atossa Genetics

Atossa Genetics Inc. is focused on improving breast health through the development of laboratory services, medical devices and therapeutics. The laboratory services are being developed by its subsidiary, The National Reference Laboratory for Breast Health, Inc. The laboratory services and the Company's medical devices are being developed so they can be used as companions to therapeutics to treat various breast health conditions. For more information, please visit

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, the outcome or timing of regulatory approvals needed by Atossa to sell its products, responses to regulatory matters, Atossa's ability to achieve its objectives, continue to manufacture and sell its products, recalls of products, the safety and efficacy of Atossa's products and services, performance of distributors, whether Atossa can launch and commerciailize in the United States and foreign markets the additional tests, devices and therapeutics in its pipeline in a timely and cost effective manner, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time. Atossa does not undertake any obligation to update any forward looking statement.